Skip to main content
Top
Published in: Virology Journal 1/2017

Open Access 01-12-2017 | Research

Negative immune factors might predominate local tumor immune status and promote carcinogenesis in cervical carcinoma

Authors: Minyi Zhao, Yang Li, Xing Wei, Qian Zhang, Hongran Jia, Shimin Quan, Di Cao, Li Wang, Ting Yang, Juan Zhao, Meili Pei, Sijuan Tian, Yang Yu, Yanping Guo, Xiaofeng Yang

Published in: Virology Journal | Issue 1/2017

Login to get access

Abstract

Background

The disequilibrium of local immune microenvironment is an essential element during tumorigenesis.

Method

By conducting real-time polymerase chain reaction, we identified the mRNA level of immune factors, FoxP3 (forkhead box protein P3), CCL22/CCR4 (chemokine (C-C motif) ligand 22/CC chemokine receptor 4), OX40L/OX40 (tumor necrosis factor superfamily member 4/tumor necrosis factor receptor superfamily member 4) and Smad3 (SMAD family member 3) in neoplastic foci and its periphery tissues from 30 cases of squamous cervical carcinoma and 20 cases of normal cervix.

Result

The FoxP3, CCL22 and CCR4 mRNA level in local immune microenvironment of normal cervix was lower than that in cervical cancer. While OX40L, OX40 and Smad3 mRNA level profile in normal cervix was higher than that in cervical cancer. Beyond individual effect, the pairwise positive correlations were demonstrated among the mRNA level of FoxP3, CCL22 and CCR4. The mRNA level of OX40 negatively correlated with CCL22, but positively correlated with Smad3. Moreover, the mRNA level of FoxP3 and CCL22 was increased while Smad3 was decreased in cervical tissue with HPV (human papilloma virus) infection.

Conclusion

Our data yields insight into the roles of these immune factors in cervical carcinogenesis. It may therefore be that, in microenvironment of cervical squamous cell carcinoma, along with the context of HPV infection, negative immune regulators FoxP3, CCL22 and CCR4 might overwhelm positive immune factors OX40L, OX40 and Smad3, giving rise to an immunosuppressive status and promote the progression of cervical carcinogenesis.

Trial registration

Not applicable.
Literature
1.
go back to reference Wu H, Zhang J. miR-124 rs531564 polymorphism influences genetic susceptibility to cervical cancer [J]. Int J Clin Exp Med. 2014;7(12):5847–51.PubMedPubMedCentral Wu H, Zhang J. miR-124 rs531564 polymorphism influences genetic susceptibility to cervical cancer [J]. Int J Clin Exp Med. 2014;7(12):5847–51.PubMedPubMedCentral
2.
go back to reference Zhao EF, Bao L, Li C, et al. Changes in epidemiology and clinical characteristics of cervical cancer over the past 50 years [J]. Di Yi Jun Yi Da Xue Xue Bao. 2005;25(6):605–9.PubMed Zhao EF, Bao L, Li C, et al. Changes in epidemiology and clinical characteristics of cervical cancer over the past 50 years [J]. Di Yi Jun Yi Da Xue Xue Bao. 2005;25(6):605–9.PubMed
3.
go back to reference de Sanjose S, Diaz M, Castellsague X, et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis [J]. Lancet Infect Dis. 2007;7(7):453–9.CrossRefPubMed de Sanjose S, Diaz M, Castellsague X, et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis [J]. Lancet Infect Dis. 2007;7(7):453–9.CrossRefPubMed
4.
go back to reference Peto J, Gilham C, Deacon J, et al. Cervical HPV infection and neoplasia in a large population-based prospective study: the Manchester cohort [J]. Br J Cancer. 2004;91(5):942–53.PubMedPubMedCentral Peto J, Gilham C, Deacon J, et al. Cervical HPV infection and neoplasia in a large population-based prospective study: the Manchester cohort [J]. Br J Cancer. 2004;91(5):942–53.PubMedPubMedCentral
5.
go back to reference Stanley MA. Immune responses to human papilloma viruses [J]. Indian J Med Res. 2009;130(3):266–76.PubMed Stanley MA. Immune responses to human papilloma viruses [J]. Indian J Med Res. 2009;130(3):266–76.PubMed
6.
go back to reference Langers I, Renoux U, et al. Natural killer and dendritic cells collaborate in the immune response induced by the vaccine against uterine cervical cancer [J]. Eur J Immunol. 2014;44(12):3585–95.CrossRefPubMed Langers I, Renoux U, et al. Natural killer and dendritic cells collaborate in the immune response induced by the vaccine against uterine cervical cancer [J]. Eur J Immunol. 2014;44(12):3585–95.CrossRefPubMed
7.
go back to reference Senba M, Mori N, et al. Mechanisms of virus immune evasion lead to deveopment from chronic inflammation to cancer formation associated with human papillomavirus infection [J]. Oncol Rev. 2012;6(2):e17. doi:10.4081/oncol.2012.e17.eCollection. 2012. Senba M, Mori N, et al. Mechanisms of virus immune evasion lead to deveopment from chronic inflammation to cancer formation associated with human papillomavirus infection [J]. Oncol Rev. 2012;6(2):e17. doi:10.​4081/​oncol.​2012.​e17.​eCollection. 2012.
8.
go back to reference Rincon-Orozco B, Halec G, Rosenberger S, et al. Epigenetic silencing of interferon-kappa in human papillomavirus type 16-positive cells [J]. Cancer Res. 2009;69(22):8718–25.CrossRefPubMed Rincon-Orozco B, Halec G, Rosenberger S, et al. Epigenetic silencing of interferon-kappa in human papillomavirus type 16-positive cells [J]. Cancer Res. 2009;69(22):8718–25.CrossRefPubMed
9.
go back to reference Leong CM, Doorbar J, Nindl I, et al. Deregulation of E-cadherin by human papillomavirus is not confined to high-risk, cancer-causing types [J]. Br J Dermatol. 2010;163(6):1253–63.CrossRefPubMed Leong CM, Doorbar J, Nindl I, et al. Deregulation of E-cadherin by human papillomavirus is not confined to high-risk, cancer-causing types [J]. Br J Dermatol. 2010;163(6):1253–63.CrossRefPubMed
11.
go back to reference Li YQ, Liu FF, Zhang XM, et al. Tumor secretion of CCL22 activates intratumoral treg infiltration and is independent prognostic predictor of breast cancer [J]. PLoS One. 2013;8(10):e76379.CrossRefPubMedPubMedCentral Li YQ, Liu FF, Zhang XM, et al. Tumor secretion of CCL22 activates intratumoral treg infiltration and is independent prognostic predictor of breast cancer [J]. PLoS One. 2013;8(10):e76379.CrossRefPubMedPubMedCentral
13.
go back to reference Xu T, Ni MM, Huang C, et al. NLRC5 mediates IL-6 and IL-1beta secretion in LX-2 cells and modulated by the NF-kappaB/Smad3 pathway [J]. Inflammation. 2015;38(5):1794–804.CrossRefPubMed Xu T, Ni MM, Huang C, et al. NLRC5 mediates IL-6 and IL-1beta secretion in LX-2 cells and modulated by the NF-kappaB/Smad3 pathway [J]. Inflammation. 2015;38(5):1794–804.CrossRefPubMed
14.
go back to reference Wolfraim LA, Fernandez TM, Mamura M, et al. Loss of Smad3 in acute T-cell lymphoblastic leukemia [J]. N Engl J Med. 2004;351(6):552–9.CrossRefPubMed Wolfraim LA, Fernandez TM, Mamura M, et al. Loss of Smad3 in acute T-cell lymphoblastic leukemia [J]. N Engl J Med. 2004;351(6):552–9.CrossRefPubMed
15.
go back to reference Kim SH, Ahn S, Kim KH, et al. Smad3 and Smad3 phosphoisoforms are prognostic markers of gastric carcinoma [J]. Dig Dis Sci. 2013;58(4):989–97.CrossRefPubMed Kim SH, Ahn S, Kim KH, et al. Smad3 and Smad3 phosphoisoforms are prognostic markers of gastric carcinoma [J]. Dig Dis Sci. 2013;58(4):989–97.CrossRefPubMed
16.
go back to reference Collison LW, Workman CJ, Kuo TT, et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function [J]. Nature. 2007;450(7169):566–9.CrossRefPubMed Collison LW, Workman CJ, Kuo TT, et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function [J]. Nature. 2007;450(7169):566–9.CrossRefPubMed
17.
go back to reference Uhlig HH, Coombes J, Mottet C, et al. Characterization of FoxP3(+)CD4(+)CD25(+) and IL-10-secreting CD4(+)CD25(+) T cells during cure of colitis [J]. J Immunol. 2006;177(9):5852–60.CrossRefPubMed Uhlig HH, Coombes J, Mottet C, et al. Characterization of FoxP3(+)CD4(+)CD25(+) and IL-10-secreting CD4(+)CD25(+) T cells during cure of colitis [J]. J Immunol. 2006;177(9):5852–60.CrossRefPubMed
18.
go back to reference Kim M, Grimmig T, Grimm M, et al. Expression of FoxP3 in colorectal cancer but not in treg cells correlates with disease progression in patients with colorectal cancer [J]. PLoS One. 2013;8(1):e53630.CrossRefPubMedPubMedCentral Kim M, Grimmig T, Grimm M, et al. Expression of FoxP3 in colorectal cancer but not in treg cells correlates with disease progression in patients with colorectal cancer [J]. PLoS One. 2013;8(1):e53630.CrossRefPubMedPubMedCentral
19.
go back to reference De Reuver PR, Mehta S, Gill P, et al. Immunoregulatory forkhead Box protein p3-positive lymphocytes Are associated with overall survival in patients with pancreatic neuroendocrine tumors [J]. J Am Coll Surg. 2016;223(3):281–7.CrossRef De Reuver PR, Mehta S, Gill P, et al. Immunoregulatory forkhead Box protein p3-positive lymphocytes Are associated with overall survival in patients with pancreatic neuroendocrine tumors [J]. J Am Coll Surg. 2016;223(3):281–7.CrossRef
20.
go back to reference Lin SZ, Chen KJ, Xu ZY, et al. Prediction of recurrence and survial in hepatocellular carcinoma based on two Cox models mainly determined by FoxP3+ regulatory T cells [J]. Cancer Prev Res (Phila). 2013;6(6):594–602.CrossRef Lin SZ, Chen KJ, Xu ZY, et al. Prediction of recurrence and survial in hepatocellular carcinoma based on two Cox models mainly determined by FoxP3+ regulatory T cells [J]. Cancer Prev Res (Phila). 2013;6(6):594–602.CrossRef
21.
go back to reference Winkler I, Wilczynska B, Bojarska-Junak A, et al. Regulatory T lymphocytes and transforming growth factor beta in epithelial ovarian tumors-prognostic significance [J]. J Ovarian Res. 2015;8:39.CrossRefPubMedPubMedCentral Winkler I, Wilczynska B, Bojarska-Junak A, et al. Regulatory T lymphocytes and transforming growth factor beta in epithelial ovarian tumors-prognostic significance [J]. J Ovarian Res. 2015;8:39.CrossRefPubMedPubMedCentral
22.
go back to reference Kumai T, Nagato T, Kobayashi H, et al. CCL17 and CCL22/CCR4 signaling is a strong candidate for novel targeted therapy against nasal natural killer/T-cell lymphoma [J]. Cancer Immunol Immunother. 2015;64(6):697–705.CrossRefPubMedPubMedCentral Kumai T, Nagato T, Kobayashi H, et al. CCL17 and CCL22/CCR4 signaling is a strong candidate for novel targeted therapy against nasal natural killer/T-cell lymphoma [J]. Cancer Immunol Immunother. 2015;64(6):697–705.CrossRefPubMedPubMedCentral
23.
go back to reference Nakamura ES, Koizumi K, Kobayashi M, et al. RANKL-induced CCL22/macrophage-derived chemokine produced from osteoclasts potentially promotes the bone metastasis of lung cancer expressing its receptor CCR4 [J]. Clin Exp Metastasis. 2006;23(1):9–18.CrossRefPubMed Nakamura ES, Koizumi K, Kobayashi M, et al. RANKL-induced CCL22/macrophage-derived chemokine produced from osteoclasts potentially promotes the bone metastasis of lung cancer expressing its receptor CCR4 [J]. Clin Exp Metastasis. 2006;23(1):9–18.CrossRefPubMed
24.
go back to reference Gobert M, Treilleux I, Bendriss-Vermare N, et al. Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome [J]. Cancer Res, 2009, 69 (5): 2000–2009. Gobert M, Treilleux I, Bendriss-Vermare N, et al. Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome [J]. Cancer Res, 2009, 69 (5): 2000–2009.
25.
go back to reference Woo YL, van den Hende M, Sterling JC, et al. A prospective study on the natural course of low-grade aquamous intraepithelial lesions and the presence of HPV16 E2-, E6 and E7-specific T-cell responses [J]. Int J Cancer. 2010;126(1):133–41.CrossRefPubMed Woo YL, van den Hende M, Sterling JC, et al. A prospective study on the natural course of low-grade aquamous intraepithelial lesions and the presence of HPV16 E2-, E6 and E7-specific T-cell responses [J]. Int J Cancer. 2010;126(1):133–41.CrossRefPubMed
Metadata
Title
Negative immune factors might predominate local tumor immune status and promote carcinogenesis in cervical carcinoma
Authors
Minyi Zhao
Yang Li
Xing Wei
Qian Zhang
Hongran Jia
Shimin Quan
Di Cao
Li Wang
Ting Yang
Juan Zhao
Meili Pei
Sijuan Tian
Yang Yu
Yanping Guo
Xiaofeng Yang
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Virology Journal / Issue 1/2017
Electronic ISSN: 1743-422X
DOI
https://doi.org/10.1186/s12985-016-0670-8

Other articles of this Issue 1/2017

Virology Journal 1/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.